News Scan for Mar 01, 2021 umn.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from umn.edu Daily Mail and Mail on Sunday newspapers.
(UPDATED) There is no difference in in-hospital outcomes or longer-term mortality between patients undergoing revascularization with either a durable-polymer DES or newer technology with a bioabsorbable polymer, according to the results of a retrospective analysis.
Among more than 53,000 consecutive PCIs performed between 2015 and 2018 in Michigan, researchers found there was no difference in the risk of in-hospital mortality or stent thrombosis between patients who received the bioabsorbable-polymer everolimus-eluting stent (Synergy; Boston Scientific) and those treated with either the durable-polymer everolimus-eluting stent (Xience; Abbott Vascular) or the durable-polymer zotarolimus-eluting stent (Resolute; Medtronic).
Importantly, at 2 years, there was also no significant difference in the risk of death between the stent groups.
click to enlarge
Scenes from Beneath The Surface: A Film About Living with MS Last December, it dawned on Marylou Kandur that it had been over nine months since the members of her Parkinson s disease support group had seen each other s faces. While many other groups had pivoted online after COVID hit back in March, her Rhinebeck Parkinson s Support Group most of them senior citizens lacking in digital fluency lagged behind. Let me see if I can get these people together, thought Kandur, a retired entrepreneur in Red Hook who has had a manageable form of Parkinson s for 22 years. But what will I say to them?
Numerous studies have listed pregnancy, physical and emotional stress, and sleeping patterns as factors that increase the risk for heart disease and stroke in women.
P=0.046)
The TAVR group had had more deaths and strokes between 1 and 2 years compared with the SAVR group, according to the PARTNER 3 investigators led by Martin Leon, MD, of Columbia University Irving Medical Center in New York City. Their report was published in the March 9 issue of the Clearly, ongoing assessment of clinical and echocardiographic findings is needed in younger and low-risk patients and planned follow-up in PARTNER 3 will continue through at least 10 years, Leon and colleagues wrote.
The convergence in death and stroke came as no surprise to cardiac surgeon Joseph Bavaria, MD, of the Hospital of the University of Pennsylvania in Philadelphia, who participated in the trial.